Research
PT-141
Melanocortin Receptor Agonist | Sexual Health Research
$0.00
Size
Out of stock
Description
PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin receptors in the central nervous system. It has been studied for its role in sexual desire, arousal, and neurological signaling pathways.
Research
PT-141 (Bremelanotide) — Research Notes PT-141 is a synthetic melanocortin receptor agonist studied for its effects on sexual desire, arousal, and central nervous system signaling. Key Research Findings: Mechanism of Action: Primarily activates melanocortin receptors, including MC4R, involved in neurological pathways associated with sexual behavior. Sexual Function: Clinical studies have investigated its potential to improve sexual desire and arousal. Neurological Activity: Acts through central nervous system pathways rather than directly increasing blood flow. Clinical Research: Bremelanotide has demonstrated efficacy in certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). - Safety Observations: Reported effects include nausea, flushing, headaches, temporary blood pressure increases, and skin pigmentation changes. Research Summary: PT-141 remains an important compound in melanocortin receptor research. Its prescription formulation, Vyleesi, is FDA-approved for a specific form of low sexual desire in premenopausal women, but not for men or sexual performance enhancement.
RESEARCH USE ONLY. Not for human or veterinary consumption. This product is sold to qualified researchers aged 21 or older for laboratory research purposes.